Literature DB >> 21928258

Triple therapy for corneal neovascularization: a case report.

Daniele Veritti1, Stefano Vergallo, Paolo Lanzetta.   

Abstract

PURPOSE: To investigate the effect of the combination of photodynamic therapy with verteporfin and subconjunctival bevacizumab and triamcinolone acetonide on corneal neovascularization secondary to corneal graft failure.
METHODS: A patient with extensive deep and superficial corneal neovascularization underwent same day triple therapy with subconjunctival bevacizumab (1.25 mg), subconjunctival triamcinolone acetonide (40 mg), and photodynamic therapy with verteporfin (fluence 50 J/cm², irradiance 300 mW/cm²).
RESULTS: A complete angiographic new vessel regression was obtained and was discernible starting 7 days after combination therapy. Three months after treatment, an initial new-vessel sprout was noted. Triple therapy was then repeated. No angiographic evidence of corneal neovascularization was detectable for the entire 6-month follow-up duration.
CONCLUSIONS: Triple therapy may offer a promising tool in the treatment of corneal neovascularization.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21928258     DOI: 10.5301/ejo.5000050

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  5 in total

1.  Synergism between the tyrosine kinase inhibitor sunitinib and Anti-TNF antibody protects against lethal dengue infection.

Authors:  Emilie Branche; William Weihao Tang; Karla M Viramontes; Matthew Perry Young; Nicholas Sheets; Yunichel Joo; Anh-Viet T Nguyen; Sujan Shresta
Journal:  Antiviral Res       Date:  2018-07-30       Impact factor: 5.970

Review 2.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

3.  Photodynamic therapy with verteporfin for corneal neovascularization.

Authors:  Abdullah A Al-Torbak
Journal:  Middle East Afr J Ophthalmol       Date:  2012 Apr-Jun

Review 4.  Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization.

Authors:  Tariq Al-Debasi; Abdulkareem Al-Bekairy; Abdulmalik Al-Katheri; Shmeylan Al Harbi; Mahmoud Mansour
Journal:  Saudi J Ophthalmol       Date:  2017-03-08

5.  Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization.

Authors:  Hyeon Jeong Yoon; Je Moon Woo; Yong Sok Ji; Kyung Chul Yoon
Journal:  Medicina (Kaunas)       Date:  2019-11-07       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.